Cancer Drugs

U.S. patent issued for new formulations of anticancer drug

Published in Cancer Weekly, June 17th, 2003

SuperGen, Inc., (NASDAQ:SUPG) announced that it has been issued U.S. Patent No. 6,538,020, which covers new and improved formulations of the anticancer drug paclitaxel, methods of manufacturing these formulations, kits containing these formulations, and methods of treating cancer patients using these formulations.

The new and improved formulations include pharmaceutically acceptable, water miscible solubilizers other than Cremophor which are believed to have improved long-term stability and may reduce adverse side-effects relative to existing formulations.

"Paclitaxel is poorly soluble in water, so Cremophor is used to help the drug dissolve," said...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-06-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry